PLX (Protalix BioTherapeutics) Momentum Rank: 3 (As of Aug. 18, 2026) — 25% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLX Protalix BioTherapeutics Inc PLX
54 GF Score
Price $2.34
GF Value $2.20
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Protalix BioTherapeutics Momentum Rank?

Protalix BioTherapeutics PLX +2.18% 54 Momentum Rank is 3 as of Aug. 18, 2026, which is 25% below its 10-year median of 4.00. GuruFocus rates PLX with a GF Score™ of 54/100 and a GF Value™ of $2.20 (Fairly Valued). The stock has 4 warning signs investors should review.

Protalix BioTherapeutics has the Momentum Rank of 3.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Protalix BioTherapeutics Momentum Rank Related Terms

PLX vs GLSI, DTIL, NERV: Momentum Rank Comparison

For the Biotechnology subindustry, Protalix BioTherapeutics's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Protalix BioTherapeutics Momentum Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's Momentum Rank falls into.


PLX
54GF Score
Protalix BioTherapeutics Inc PLX
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 3 mean?
Protalix BioTherapeutics (PLX) has a Momentum Rank of 3 as of Aug. 18, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Protalix BioTherapeutics and its competitors. This is 25% below median its historical median of 4.00. Over the past decade, Protalix BioTherapeutics' Momentum Rank has ranged from 1.00 to 10.00.
Is Protalix BioTherapeutics' Momentum Rank too high?
Protalix BioTherapeutics' current Momentum Rank of 3 is 25% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Protalix BioTherapeutics has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' Momentum Rank compare to GLSI and DTIL?
Protalix BioTherapeutics' Momentum Rank of 3 can be compared against companies in the Biotechnology industry. Historically, Protalix BioTherapeutics' own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Biotechnology company?
A good Momentum Rank depends on the Biotechnology industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Protalix BioTherapeutics and its competitors. Protalix BioTherapeutics's current Momentum Rank is 3, which is 25% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (PLX) is currently considered Fairly Valued. The stock's GF Value™ is $2.20, compared to a current price of $2.34 — trading 6.4% above its estimated fair value. The current Momentum Rank is 3, which is 25% below median its 10-year median of 4.00. Protalix BioTherapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Protalix BioTherapeutics (PLX), the current Momentum Rank is 3 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Protalix BioTherapeutics (PLX) Overvalued in 2026?

Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued. The current stock price of $2.34 is trading 6.4% above its estimated GF Value™ of $2.20. GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.

Key valuation signals for PLX:

  • Momentum Rank: 3 (25% below median its 10-year median of 4.00)
  • GF Value™: $2.20 vs. price of $2.34 (6.4% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the PLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protalix BioTherapeutics Business Description

Other Exchanges PBDA:Germany
Address 2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
54GF Score

Get the complete analysis for PLX

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.34
Price
$2.20
GF Value